BPIQ Blog

Apr 8, 201910 min read

Incyte (INCY) appears to have the stronger hand in its patent disputes with Concert (CNCE), regardle

BIopharma companies (Concert and Incyte) patent dispute.

Nov 30, 20182 min read

Download Full Article Summary Amarin has patent protection for Vascepa® out to 2030, including protection related to the possible...

Our platform helps you uncover your next biotech investment opportunity